
Greenwich LifeSciences, Inc.: updates and filings
Price
$19.25
November 20, 2026Market cap $283M
What Ploutos Investor adds for Greenwich LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
June 2026
December 2025
July 2025
December 2024
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 26, 2026Additional annual meeting materialFormDEFA14A
- Oct 26, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Oct 26, 2026Annual meeting proxy statementFormDEF 14A
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jun 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Jun 1, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 31, 2026Notice that the annual report will be filed lateFormNT 10-K
- Dec 18, 2025Shareholder voteForm8-K
- Nov 14, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 3, 2025Annual report to shareholdersfor the period to Dec 31, 2024FormARS
- Nov 3, 2025Additional annual meeting materialFormDEFA14A
- Nov 3, 2025Annual meeting proxy statementFormDEF 14A
- Aug 14, 2025Quarterly reportfor the period to Jun 30, 2025Form10-Q
- Jul 24, 2025Change of auditorForm8-K
- May 20, 2025Quarterly reportfor the period to Mar 31, 2025Form10-Q
- May 15, 2025Notice that the quarterly report will be filed lateFormNT 10-Q
- Apr 15, 2025Annual reportfor the period to Dec 31, 2024Form10-K
- Mar 31, 2025Notice that the annual report will be filed lateFormNT 10-K
- Dec 20, 2024Shares registered for employeesFormS-8
- Dec 19, 2024Shareholder voteForm8-K
- Nov 14, 2024Quarterly reportfor the period to Sep 30, 2024Form10-Q
- Nov 1, 2024Additional annual meeting materialFormDEFA14A
- Nov 1, 2024Annual report to shareholdersfor the period to Dec 31, 2023FormARS
- Nov 1, 2024Annual meeting proxy statementFormDEF 14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 26, 2026 | DEFA14A | Additional annual meeting material | Document |
| Oct 26, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Oct 26, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jun 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Jun 1, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 31, 2026 | NT 10-K | Notice that the annual report will be filed late | Document |
| Dec 18, 2025 | 8-K | Shareholder vote | Document |
| Nov 14, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 3, 2025 | ARS | Annual report to shareholdersfor the period to Dec 31, 2024 | Document |
| Nov 3, 2025 | DEFA14A | Additional annual meeting material | Document |
| Nov 3, 2025 | DEF 14A | Annual meeting proxy statement | Document |
| Aug 14, 2025 | 10-Q | Quarterly reportfor the period to Jun 30, 2025 | Document |
| Jul 24, 2025 | 8-K | Change of auditor | Document |
| May 20, 2025 | 10-Q | Quarterly reportfor the period to Mar 31, 2025 | Document |
| May 15, 2025 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Apr 15, 2025 | 10-K | Annual reportfor the period to Dec 31, 2024 | Document |
| Mar 31, 2025 | NT 10-K | Notice that the annual report will be filed late | Document |
| Dec 20, 2024 | S-8 | Shares registered for employees | Document |
| Dec 19, 2024 | 8-K | Shareholder vote | Document |
| Nov 14, 2024 | 10-Q | Quarterly reportfor the period to Sep 30, 2024 | Document |
| Nov 1, 2024 | DEFA14A | Additional annual meeting material | Document |
| Nov 1, 2024 | ARS | Annual report to shareholdersfor the period to Dec 31, 2023 | Document |
| Nov 1, 2024 | DEF 14A | Annual meeting proxy statement | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 27, 2020.
The full analysis
What do Greenwich LifeSciences's filings show?
The filings are where every one of Greenwich LifeSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.